Armis Advisers’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.7M Buy
6,463
+45
+0.7% +$17.9K 0.23% 80
2026
Q2
$2.35M Buy
6,418
+323
+5% +$111K 0.22% 78
2026
Q1
$2.05M Sell
6,095
-66
-1% -$23.5K 0.2% 87
2025
Q4
$2.14M Buy
6,161
+296
+5% +$93.9K 0.24% 67
2025
Q3
$1.72M Buy
5,865
+793
+16% +$230K 0.16% 95
2025
Q2
$1.48M Buy
5,072
+245
+5% +$69.4K 0.12% 142
2025
Q1
$1.44M Buy
4,827
+3,862
+400% +$1.14M 0.13% 129
2024
Q4
$251K Buy
+965
New +$286K 0.03% 300

Other funds holding AMGN

Armis Advisers's AMGN Position: Q3 2026 in Review

Armis Advisers increased its Amgen (AMGN) stake by 0.7% in Q3 2026, buying an estimated $17.9K and bringing the position to 6,463 shares worth $2.7M. The position accounts for 0.23% of the portfolio, ranked #80.

Armis Advisers first reported a position in AMGN in Q4 2024 and has held it in 8 quarters since. 2,024 funds tracked by Wall St. Rank hold AMGN as of Q3 2026.

  • Armis Advisers held 6,463 shares of Amgen worth $2.7M as of Q3 2026.
  • Armis Advisers bought 45 Amgen shares in Q3 2026, an estimated $17.9K.
  • Amgen made up 0.23% of Armis Advisers's portfolio in Q3 2026, its #80 holding.
  • Armis Advisers first reported a position in Amgen in Q4 2024 and has held it in 8 quarters since.
  • 2,024 funds tracked by Wall St. Rank held Amgen as of Q3 2026.

Based on Armis Advisers's 13F filing for Q3 2026, filed 13 Oct 2026.